RespireRx Pharmaceuticals Inc (RSPI)

[myostrain]

There is another strong negative towards financing before RD results.
Any agency involved will likely utilize the R+R data+forecasts.
Until tox results are in and are positive or RD results are in, the primary positive COR has in financing would be the SGP ampakine progress.

Cortex will do something to help there balance line, financing or a deal with another company. There seems to be no logic to do a financing before there are any positive tox or RD data. Prior to tox/RD data, financiers would use probability data that would lean towards the negative likeliehoods. Post tox/RD data financing, if tox or RD data were negative or inconclusive, the deal would likely have a nonsignificant difference in financing compared to a Pre tox/RD financing.
The only rational reasoning to do a financing pre RD results would be related to the timeline relating to the current cash burn rate and the timeline for performing a financing and receiving the financing. Prior discussion of the burn rate suggest there is enough time to wait until later in the year before taking the plunge.